{"transactions":[{"id":809481,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-13T20:46:24.000Z","date":"2026-04-09","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates."}],"balance_after":750000,"derivative":{"exercise_price":9.54,"expiration_date":"2036-04-08","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001604834-26-000008","document":"form4-04132026_080417.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000160483426000008/form4-04132026_080417.xml","form_type":"4"}},{"id":857879,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-03-06T00:14:48.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":22254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each RSU represents a contingent right to receive one (1) share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On March 3, 2025, the reporting person was granted 22,254 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On March 3, 2025, the reporting person was granted 22,254 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22254},"source":{"system":"sec-edgar","filing":"0001604834-26-000006","document":"form4-03062026_120343.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000160483426000006/form4-03062026_120343.xml","form_type":"4"}},{"id":857878,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT and CEO"}}],"security":"Common Stock","published_at":"2026-03-06T00:14:48.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":5156,"price":5.37,"value":27687.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (\"RSU\") pursuant to mandatory \"sell to cover\" policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":57926,"source":{"system":"sec-edgar","filing":"0001604834-26-000006","document":"form4-03062026_120343.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000160483426000006/form4-03062026_120343.xml","form_type":"4"}},{"id":857877,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT and CEO"}}],"security":"Common Stock","published_at":"2026-03-06T00:14:48.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":22254,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":63082,"source":{"system":"sec-edgar","filing":"0001604834-26-000006","document":"form4-03062026_120343.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000160483426000006/form4-03062026_120343.xml","form_type":"4"}},{"id":950009,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T00:51:49.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":10834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F7","text":"RSUs convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each RSU represents a contingent right to receive one (1) share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"On October 1, 2024, the reporting person was granted 32,500 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the \"Plan\")) through the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"On October 1, 2024, the reporting person was granted 32,500 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the \"Plan\")) through the applicable vesting dates."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10834},"source":{"system":"sec-edgar","filing":"0001604834-26-000002","document":"form4-01062026_120146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000160483426000002/form4-01062026_120146.xml","form_type":"4"}},{"id":950008,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-06T00:51:49.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":2586,"price":6.88,"value":17791.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (\"RSU\") pursuant to mandatory \"sell to cover\" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of common stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald & Co. entered into in connection with the Issuer's private placement in December 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":40828,"source":{"system":"sec-edgar","filing":"0001604834-26-000002","document":"form4-01062026_120146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000160483426000002/form4-01062026_120146.xml","form_type":"4"}},{"id":950007,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-06T00:51:49.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":10834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reported number of shares in this Form 4 has been adjusted to reflect the impact of the Issuer's 10-for-1 reverse stock split completed on September 17, 2025 (the \"Reverse Stock Split\")."}],"balance_after":43414,"source":{"system":"sec-edgar","filing":"0001604834-26-000002","document":"form4-01062026_120146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000160483426000002/form4-01062026_120146.xml","form_type":"4"}},{"id":957900,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-29T21:17:39.000Z","date":"2025-12-24","kind":"grant","planned":false,"acquired":true,"shares":133526,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On September 25, 2025, the reporting person was granted an option to purchase 133,526 shares of common stock. The option was scheduled to vest only upon satisfaction of both a milestone requirement (the \"Milestone Requirement\") and a service-based requirement (the \"Service-Based Requirement\"). The Milestone Requirement was satisfied on December 23, 2025. The Service-Based Requirement will be satisfied as to 50% of the total number of shares granted under the option on December 23, 2026 and as to 1/36th of the remaining 50% on the 23rd day of each month thereafter, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates."}],"balance_after":133526,"derivative":{"exercise_price":3.81,"expiration_date":"2035-09-24","underlying":"Common Stock","underlying_shares":133526},"source":{"system":"sec-edgar","filing":"0001604834-25-000004","document":"form4-12292025_091231.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000160483425000004/form4-12292025_091231.xml","form_type":"4"}},{"id":1094233,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-07-02T20:34:41.000Z","date":"2025-06-30","kind":"exercise","planned":false,"acquired":false,"shares":108334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"RSUs convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each RSU represents a contingent right to receive one (1) share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On October 1, 2024, the reporting person was granted 325,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the \"Plan\")) through the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"On October 1, 2024, the reporting person was granted 325,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the \"Plan\")) through the applicable vesting dates."}],"balance_after":108333,"derivative":{"underlying":"Common Stock","underlying_shares":108334},"source":{"system":"sec-edgar","filing":"0001415889-25-019069","document":"form4-07022025_080737.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588925019069/form4-07022025_080737.xml","form_type":"4"}},{"id":1094232,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-02T20:34:41.000Z","date":"2025-07-01","kind":"sale","planned":false,"acquired":false,"shares":25123,"price":0.2935,"value":7373.6005,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (\"RSU\") pursuant to mandatory \"sell to cover\" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.2854 to $0.3031, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":325802,"source":{"system":"sec-edgar","filing":"0001415889-25-019069","document":"form4-07022025_080737.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588925019069/form4-07022025_080737.xml","form_type":"4"}},{"id":1094231,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-02T20:34:41.000Z","date":"2025-06-30","kind":"exercise","planned":false,"acquired":true,"shares":108334,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":350925,"source":{"system":"sec-edgar","filing":"0001415889-25-019069","document":"form4-07022025_080737.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588925019069/form4-07022025_080737.xml","form_type":"4"}},{"id":1226361,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-03-04T21:29:47.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":222543,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one (1) share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the \"Plan\")) through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the \"Plan\")) through the vesting date."}],"balance_after":222543,"derivative":{"underlying":"Common Stock","underlying_shares":222543},"source":{"system":"sec-edgar","filing":"0001415889-25-006536","document":"form4-03042025_090341.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588925006536/form4-03042025_090341.xml","form_type":"4"}},{"id":1226360,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T21:29:47.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":333815,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates."}],"balance_after":333815,"derivative":{"exercise_price":0.3762,"expiration_date":"2035-03-02","underlying":"Common Stock","underlying_shares":333815},"source":{"system":"sec-edgar","filing":"0001415889-25-006536","document":"form4-03042025_090341.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588925006536/form4-03042025_090341.xml","form_type":"4"}},{"id":1313425,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T22:04:12.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":false,"shares":108333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"RSUs convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each RSU represents a contingent right to receive one (1) share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On October 3, 2024, the reporting person was granted 325,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the \"Plan\")) through the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"On October 3, 2024, the reporting person was granted 325,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the \"Plan\")) through the applicable vesting dates."}],"balance_after":216667,"derivative":{"underlying":"Common Stock","underlying_shares":108333},"source":{"system":"sec-edgar","filing":"0001415889-25-000536","document":"form4-01032025_100106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588925000536/form4-01032025_100106.xml","form_type":"4"}},{"id":1313424,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-03T22:04:12.000Z","date":"2025-01-02","kind":"sale","planned":false,"acquired":false,"shares":25107,"price":0.5619,"value":14107.6233,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (\"RSU\") pursuant to mandatory \"sell to cover\" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.5414 to $0.5939, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":242591,"source":{"system":"sec-edgar","filing":"0001415889-25-000536","document":"form4-01032025_100106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588925000536/form4-01032025_100106.xml","form_type":"4"}},{"id":1313423,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-03T22:04:12.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":true,"shares":108333,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":267698,"source":{"system":"sec-edgar","filing":"0001415889-25-000536","document":"form4-01032025_100106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588925000536/form4-01032025_100106.xml","form_type":"4"}},{"id":1391467,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-04T01:50:42.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The original Form 4 incorrectly reported the Exercise Price as $0.4499."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third (1/3rd) of the shares subject to the option shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider through the applicable vesting dates."}],"balance_after":325000,"derivative":{"exercise_price":0.4257,"expiration_date":"2034-10-02","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001415889-24-024712","document":"form4a-10042024_011037.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588924024712/form4a-10042024_011037.xml","form_type":"4/A","original_submission_date":"2024-10-03"}},{"id":1391466,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-03T23:07:25.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third (1/3rd) of the shares subject to the option shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider through the applicable vesting dates."}],"balance_after":325000,"derivative":{"exercise_price":0.4499,"expiration_date":"2034-10-02","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001415889-24-024680","document":"form4-10032024_111021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588924024680/form4-10032024_111021.xml","form_type":"4"}},{"id":1391465,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-10-03T23:07:25.000Z","date":"2024-10-03","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one (1) share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third (1/3rd) of the RSUs shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the \"Plan\")) through the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-third (1/3rd) of the RSUs shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the \"Plan\")) through the applicable vesting dates."}],"balance_after":325000,"derivative":{"underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001415889-24-024680","document":"form4-10032024_111021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588924024680/form4-10032024_111021.xml","form_type":"4"}},{"id":1413502,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-09-05T23:47:27.000Z","date":"2024-09-05","kind":"sale","planned":false,"acquired":false,"shares":5032,"price":0.566,"value":2848.112,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of RSUs pursuant to mandatory \"sell to cover\" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.5505 to $0.5751, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":159365,"source":{"system":"sec-edgar","filing":"0001415889-24-022983","document":"form4-09052024_110923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588924022983/form4-09052024_110923.xml","form_type":"4"}},{"id":1413501,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-09-05T23:47:27.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 3, 2021, the reporting person was granted restricted stock units (\"RSUs\") representing 60,000 shares of Common Stock of the Issuer. The RSUs are scheduled to vest according to the following amended vesting schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest as of the date the Compensation Committee (the \"Committee\") determines that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial has been completed, and (3) one third (1/3rd) of the number of shares subject to the RSU award vest as of the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the \"LIFT-AD Readout\"), in each case subject to continued service with the Issuer through the applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On September 3, 2024, the Company completed the public readout of the topline results of its LIFT-AD Phase 2/3 clinical trial and 20,000 RSUs vested on such date."}],"balance_after":164397,"source":{"system":"sec-edgar","filing":"0001415889-24-022983","document":"form4-09052024_110923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588924022983/form4-09052024_110923.xml","form_type":"4"}},{"id":1637528,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-16T22:05:32.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates."}],"balance_after":650000,"derivative":{"exercise_price":3.66,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001415889-24-004166","document":"form4-02162024_100218.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588924004166/form4-02162024_100218.xml","form_type":"4"}},{"id":1637527,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-02-16T21:38:45.000Z","date":"2024-01-05","kind":"sale","planned":false,"acquired":false,"shares":4820,"price":2.91,"value":14026.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The reported shares were sold to cover the Issuer's tax withholding obligations in connection with the vesting of RSUs. Such sale was made pursuant to an Issuer-mandated policy and was not subject to discretion."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $2.84 to $3.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":144397,"source":{"system":"sec-edgar","filing":"0001415889-24-004153","document":"form4a-02162024_090229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588924004153/form4a-02162024_090229.xml","form_type":"4/A","original_submission_date":"2024-01-08"}},{"id":1637526,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-02-16T21:38:45.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 3, 2021, the reporting person was granted restricted stock units (\"RSUs\") representing 60,000 shares of Common Stock of the Issuer. The RSUs are scheduled to vest according to the following amended vesting schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest as of the date the Compensation Committee (the \"Committee\") determines that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial has been completed, and (3) one third (1/3rd) of the number of shares subject to the RSU award vest as of the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the \"LIFT-AD Readout\"), in each case subject to continued service with the Issuer through the applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On January 4, 2024, the Committee determined that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial had been completed and 20,000 RSUs vested and settled on such date.  The original Form 4 incorrectly reported the determination date as January 4, 2023."}],"balance_after":149217,"source":{"system":"sec-edgar","filing":"0001415889-24-004153","document":"form4a-02162024_090229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000141588924004153/form4a-02162024_090229.xml","form_type":"4/A","original_submission_date":"2024-01-08"}},{"id":1683690,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:40:49.000Z","date":"2024-01-05","kind":"sale","planned":false,"acquired":false,"shares":4820,"price":2.91,"value":14026.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The reported shares were sold to cover the Issuer's tax withholding obligations in connection with the vesting of RSUs. Such sale was made pursuant to an Issuer-mandated policy and was not subject to discretion."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $2.84 to $3.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":144397,"source":{"system":"sec-edgar","filing":"0001209191-24-001150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919124001150/doc4.xml","form_type":"4"}},{"id":1683689,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:40:49.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On November 3, 2021, the reporting person was granted restricted stock units (\"RSUs\") representing 60,000 shares of Common Stock of the Issuer. The RSUs are scheduled to vest according to the following amended vesting schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest as of the date the Compensation Committee (the \"Committee\") determines that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial has been completed, and (3) one third (1/3rd) of the number of shares subject to the RSU award vest as of the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the \"LIFT-AD Readout\"), in each case subject to continued service with the Issuer through the applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On January 4, 2023, the Committee determined that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial had been completed and 20,000 RSUs vested and settled on such date."}],"balance_after":149217,"source":{"system":"sec-edgar","filing":"0001209191-24-001150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919124001150/doc4.xml","form_type":"4"}},{"id":2039883,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-01T00:33:50.000Z","date":"2023-01-27","kind":"grant","acquired":true,"shares":425000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One thirty-sixth (1/36th) of the shares subject to the option will vest on February 27, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter."}],"balance_after":425000,"derivative":{"exercise_price":4.11,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0001209191-23-005818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919123005818/doc4.xml","form_type":"4"}},{"id":2039882,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-01T00:33:50.000Z","date":"2022-11-18","kind":"grant","acquired":true,"shares":662,"price":2.74,"value":1813.88,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2022 through November 18, 2022. This transaction is also exempt under Rule 16b-3(c)."},{"field":"date","element":"transactionDate","label":"F2","text":"The Purchase Period ended November 18, 2022 and is the sole Purchase Period in the Offering Period (as defined in the ESPP) that began May 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2022."}],"balance_after":129217,"source":{"system":"sec-edgar","filing":"0001209191-23-005818","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919123005818/doc4.xml","form_type":"4"}},{"id":2221788,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-24T23:51:54.000Z","date":"2022-06-23","kind":"sale","acquired":false,"shares":7960,"price":2.69,"value":21412.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The reported shares were sold to cover the Issuer's tax withholding obligations in connection with the vesting of RSUs. Such sale was made pursuant to an Issuer-mandated policy and was not subject to discretion."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $2.62 to $2.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":128555,"source":{"system":"sec-edgar","filing":"0001209191-22-039340","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919122039340/doc4.xml","form_type":"4"}},{"id":2221787,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-24T23:51:54.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On November 3, 2021, the reporting person was granted restricted stock units (\"RSUs\") representing 60,000 shares of Common Stock of the Issuer. The RSUs were scheduled to vest according to the following schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the \"LIFT-AD Readout\") and (3) one third (1/3rd) of the number of shares subject to the RSU award vest six (6) months after the LIFT-AD Readout, in each case subject to continued service with the Issuer through the applicable vesting date. On June 22, 2022, the Issuer completed the public readout of topline results of the ACT-AD Phase 2 clinical trial and 20,000 RSUs vested and settled on such date."}],"balance_after":136515,"source":{"system":"sec-edgar","filing":"0001209191-22-039340","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919122039340/doc4.xml","form_type":"4"}},{"id":2221786,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-24T23:51:54.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":757,"price":7.06,"value":5344.42,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2021 through May 18, 2022. This transaction is also exempt under Rule 16b-3(c)."},{"field":"date","element":"transactionDate","label":"F2","text":"The Purchase Period ended May 18, 2022 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2022."}],"balance_after":116515,"source":{"system":"sec-edgar","filing":"0001209191-22-039340","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919122039340/doc4.xml","form_type":"4"}},{"id":2420852,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-31T22:06:04.000Z","date":"2022-01-27","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-forty eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter."}],"balance_after":400000,"derivative":{"exercise_price":9.91,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-22-005628","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919122005628/doc4.xml","form_type":"4"}},{"id":2420851,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-31T22:06:04.000Z","date":"2021-11-18","kind":"grant","acquired":true,"shares":885,"price":12.51,"value":11071.35,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c)."},{"field":"date","element":"transactionDate","label":"F2","text":"The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021."}],"balance_after":115758,"source":{"system":"sec-edgar","filing":"0001209191-22-005628","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919122005628/doc4.xml","form_type":"4"}},{"id":2595802,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-19T21:05:50.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":50440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-fourth of the shares subject to the option vested on July 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter."}],"balance_after":100880,"derivative":{"exercise_price":1.35,"expiration_date":"2029-08-14","underlying":"Common Stock","underlying_shares":50440},"source":{"system":"sec-edgar","filing":"0001209191-21-052564","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919121052564/doc4.xml","form_type":"4"}},{"id":2595801,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-08-19T21:05:50.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":50440,"price":1.35,"value":68094.0,"ownership":{"direct":true},"balance_after":114873,"source":{"system":"sec-edgar","filing":"0001209191-21-052564","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919121052564/doc4.xml","form_type":"4"}},{"id":2595800,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-08-19T21:05:50.000Z","date":"2021-05-18","kind":"grant","acquired":true,"shares":867,"price":14.45,"value":12528.15,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP Purchase Period (as defined in the ESPP) of September 17, 2020 through May 18, 2021. This transaction is also exempt under Rule 16b-3(c)."},{"field":"date","element":"transactionDate","label":"F2","text":"The Purchase Period ended May 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began September 17, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the initial public offering price from the issuer's initial public offering."}],"balance_after":64433,"source":{"system":"sec-edgar","filing":"0001209191-21-052564","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919121052564/doc4.xml","form_type":"4"}},{"id":2842650,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-22T22:36:33.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the option will vest on January 8, 2022, and one-fourth of the shares subject to the option will vest on each year thereafter."}],"balance_after":85000,"derivative":{"exercise_price":21.15,"expiration_date":"2031-02-17","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001209191-21-012819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919121012819/doc4.xml","form_type":"4"}},{"id":3024484,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series B-1 Preferred Stock","published_at":"2020-09-22T21:15:20.000Z","date":"2020-09-22","kind":"exercise","acquired":false,"shares":6563,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Irrevocable Trust of SWL"},"footnotes":[{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6563},"source":{"system":"sec-edgar","filing":"0001209191-20-051509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919120051509/doc4.xml","form_type":"4"}},{"id":3024483,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series B-1 Preferred Stock","published_at":"2020-09-22T21:15:20.000Z","date":"2020-09-22","kind":"exercise","acquired":false,"shares":6563,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Irrevocable Trust of WGL"},"footnotes":[{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6563},"source":{"system":"sec-edgar","filing":"0001209191-20-051509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919120051509/doc4.xml","form_type":"4"}},{"id":3024482,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series B-1 Preferred Stock","published_at":"2020-09-22T21:15:20.000Z","date":"2020-09-22","kind":"exercise","acquired":false,"shares":6563,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Irrevocable Trust of OSL"},"footnotes":[{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6563},"source":{"system":"sec-edgar","filing":"0001209191-20-051509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919120051509/doc4.xml","form_type":"4"}},{"id":3024481,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series B Preferred Stock","published_at":"2020-09-22T21:15:20.000Z","date":"2020-09-22","kind":"exercise","acquired":false,"shares":13126,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13126},"source":{"system":"sec-edgar","filing":"0001209191-20-051509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919120051509/doc4.xml","form_type":"4"}},{"id":3024480,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-09-22T21:15:20.000Z","date":"2020-09-22","kind":"exercise","acquired":true,"shares":6563,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Irrevocable Trust of WGL"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."}],"balance_after":6563,"source":{"system":"sec-edgar","filing":"0001209191-20-051509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919120051509/doc4.xml","form_type":"4"}},{"id":3024479,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-09-22T21:15:20.000Z","date":"2020-09-22","kind":"exercise","acquired":true,"shares":6563,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Irrevocable Trust of SWL"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."}],"balance_after":6563,"source":{"system":"sec-edgar","filing":"0001209191-20-051509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919120051509/doc4.xml","form_type":"4"}},{"id":3024478,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-09-22T21:15:20.000Z","date":"2020-09-22","kind":"exercise","acquired":true,"shares":6563,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Irrevocable Trust of OSL"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series B-1 Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."}],"balance_after":6563,"source":{"system":"sec-edgar","filing":"0001209191-20-051509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919120051509/doc4.xml","form_type":"4"}},{"id":3024477,"issuer":{"id":1487,"kind":"organization","name":"LeonaBio, Inc.","symbol":"LONA"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-09-22T21:15:20.000Z","date":"2020-09-22","kind":"exercise","acquired":true,"shares":13126,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."}],"balance_after":63566,"source":{"system":"sec-edgar","filing":"0001209191-20-051509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000120919120051509/doc4.xml","form_type":"4"}},{"id":3667577,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T21:30:19.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of February 6, 2019 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month  thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":75000,"derivative":{"exercise_price":6.51,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-19-003031","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000089924319003031/doc4.xml","form_type":"4"}},{"id":3667576,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T21:30:19.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 6, 2018, the reporting person was granted an Option to purchase 50,000 shares of Common Stock.  The shares underlying the Option vest in two equal tranches upon the reporting person's satisfaction of certain performance criteria. On February 6, 2019, the compensation committee of the Issuer's board of directors determined that the performance criteria for one half of the shares underlying the Option were satisfied, resulting in the vesting of 25,000 of the shares of Common Stock underlying the Option."}],"balance_after":25000,"derivative":{"exercise_price":6.81,"expiration_date":"2028-08-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-19-003031","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000089924319003031/doc4.xml","form_type":"4"}},{"id":3849339,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2018-08-08T22:34:02.000Z","date":"2018-08-06","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of August 6, 2018 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month  thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":150000,"derivative":{"exercise_price":6.81,"expiration_date":"2028-08-05","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-18-021737","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604834/000089924318021737/doc4.xml","form_type":"4"}},{"id":3905127,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-05T17:40:18.000Z","date":"2018-06-01","kind":"exercise","acquired":false,"shares":22727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this stock option are fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.99,"expiration_date":"2019-04-20","underlying":"Common Stock","underlying_shares":22727},"source":{"system":"sec-edgar","filing":"0001209191-18-035863","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118035863/doc4.xml","form_type":"4"}},{"id":3905126,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-06-05T17:40:18.000Z","date":"2018-06-01","kind":"sale","acquired":false,"shares":4474,"price":18.2358,"value":81586.9692,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.20 to $18.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4."}],"balance_after":102189,"source":{"system":"sec-edgar","filing":"0001209191-18-035863","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118035863/doc4.xml","form_type":"4"}},{"id":3905125,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-06-05T17:40:18.000Z","date":"2018-06-01","kind":"sale","acquired":false,"shares":18253,"price":17.7409,"value":323824.6477,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $18.1750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4."}],"balance_after":106663,"source":{"system":"sec-edgar","filing":"0001209191-18-035863","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118035863/doc4.xml","form_type":"4"}},{"id":3905124,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-06-05T17:40:18.000Z","date":"2018-06-01","kind":"exercise","acquired":true,"shares":22727,"price":0.99,"value":22499.73,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 847 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on May 31, 2018."}],"balance_after":124916,"source":{"system":"sec-edgar","filing":"0001209191-18-035863","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118035863/doc4.xml","form_type":"4"}},{"id":4044057,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-21T17:31:52.000Z","date":"2018-02-16","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":75000,"derivative":{"exercise_price":13.55,"expiration_date":"2028-02-15","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-18-012036","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118012036/doc4.xml","form_type":"4"}},{"id":4162114,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-11-15T17:54:56.000Z","date":"2017-11-13","kind":"exercise","acquired":false,"shares":16519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":1.65,"expiration_date":"2018-07-22","underlying":"Common Stock","underlying_shares":16519},"source":{"system":"sec-edgar","filing":"0001209191-17-060971","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117060971/doc4.xml","form_type":"4"}},{"id":4162113,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-11-15T17:54:56.000Z","date":"2017-11-13","kind":"sale","acquired":false,"shares":16519,"price":10.8049,"value":178486.1431,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.55 to $11.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":99932,"source":{"system":"sec-edgar","filing":"0001209191-17-060971","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117060971/doc4.xml","form_type":"4"}},{"id":4162112,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-11-15T17:54:56.000Z","date":"2017-11-13","kind":"exercise","acquired":true,"shares":16519,"price":1.65,"value":27256.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016."}],"balance_after":116451,"source":{"system":"sec-edgar","filing":"0001209191-17-060971","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117060971/doc4.xml","form_type":"4"}},{"id":4183793,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-10-18T18:20:14.000Z","date":"2017-10-16","kind":"exercise","acquired":false,"shares":16520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested."}],"balance_after":16519,"derivative":{"exercise_price":1.65,"expiration_date":"2018-07-22","underlying":"Common Stock","underlying_shares":16520},"source":{"system":"sec-edgar","filing":"0001209191-17-057340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117057340/doc4.xml","form_type":"4"}},{"id":4183792,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-10-18T18:20:14.000Z","date":"2017-10-16","kind":"sale","acquired":false,"shares":16520,"price":12.3307,"value":203703.164,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.15 to $12.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":99932,"source":{"system":"sec-edgar","filing":"0001209191-17-057340","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117057340/doc4.xml","form_type":"4"}},{"id":4183791,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-10-18T18:20:14.000Z","date":"2017-10-16","kind":"exercise","acquired":true,"shares":16520,"price":1.65,"value":27258.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016."}],"balance_after":116452,"source":{"system":"sec-edgar","filing":"0001209191-17-057340","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117057340/doc4.xml","form_type":"4"}},{"id":4475224,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-31T17:22:17.000Z","date":"2017-01-27","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":60000,"derivative":{"exercise_price":20.4,"expiration_date":"2027-01-26","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-17-006426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117006426/doc4.xml","form_type":"4"}},{"id":4485199,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-20T18:38:42.000Z","date":"2017-01-18","kind":"exercise","acquired":false,"shares":1498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested."}],"balance_after":33039,"derivative":{"exercise_price":1.65,"expiration_date":"2018-07-22","underlying":"Common Stock","underlying_shares":1498},"source":{"system":"sec-edgar","filing":"0001209191-17-004982","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117004982/doc4.xml","form_type":"4"}},{"id":4485198,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-01-20T18:38:42.000Z","date":"2017-01-18","kind":"sale","acquired":false,"shares":1498,"price":23.0966,"value":34598.7068,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":99932,"source":{"system":"sec-edgar","filing":"0001209191-17-004982","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117004982/doc4.xml","form_type":"4"}},{"id":4485197,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-01-20T18:38:42.000Z","date":"2017-01-18","kind":"exercise","acquired":true,"shares":1498,"price":1.65,"value":2471.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016."}],"balance_after":101430,"source":{"system":"sec-edgar","filing":"0001209191-17-004982","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117004982/doc4.xml","form_type":"4"}},{"id":4495168,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-09T17:49:00.000Z","date":"2017-01-09","kind":"exercise","acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option is fully vested."}],"balance_after":34537,"derivative":{"exercise_price":1.65,"expiration_date":"2018-07-22","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001209191-17-003020","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117003020/doc4.xml","form_type":"4"}},{"id":4495167,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-09T17:49:00.000Z","date":"2017-01-06","kind":"exercise","acquired":false,"shares":1326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option is fully vested."}],"balance_after":35037,"derivative":{"exercise_price":1.65,"expiration_date":"2018-07-22","underlying":"Common Stock","underlying_shares":1326},"source":{"system":"sec-edgar","filing":"0001209191-17-003020","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117003020/doc4.xml","form_type":"4"}},{"id":4495166,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-09T17:49:00.000Z","date":"2017-01-06","kind":"exercise","acquired":false,"shares":5474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":1.265,"expiration_date":"2017-11-13","underlying":"Common Stock","underlying_shares":5474},"source":{"system":"sec-edgar","filing":"0001209191-17-003020","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117003020/doc4.xml","form_type":"4"}},{"id":4495165,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-09T17:49:00.000Z","date":"2017-01-05","kind":"exercise","acquired":false,"shares":2216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option is fully vested."}],"balance_after":5474,"derivative":{"exercise_price":1.265,"expiration_date":"2017-11-13","underlying":"Common Stock","underlying_shares":2216},"source":{"system":"sec-edgar","filing":"0001209191-17-003020","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117003020/doc4.xml","form_type":"4"}},{"id":4495164,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-01-09T17:49:00.000Z","date":"2017-01-09","kind":"sale","acquired":false,"shares":500,"price":23,"value":11500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016."}],"balance_after":99932,"source":{"system":"sec-edgar","filing":"0001209191-17-003020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117003020/doc4.xml","form_type":"4"}},{"id":4495163,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-01-09T17:49:00.000Z","date":"2017-01-09","kind":"exercise","acquired":false,"shares":500,"price":1.65,"value":825.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016."}],"balance_after":100432,"source":{"system":"sec-edgar","filing":"0001209191-17-003020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117003020/doc4.xml","form_type":"4"}},{"id":4495162,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-01-09T17:49:00.000Z","date":"2017-01-06","kind":"sale","acquired":false,"shares":6800,"price":23.0176,"value":156519.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $23.00 to $23.15, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4."}],"balance_after":99932,"source":{"system":"sec-edgar","filing":"0001209191-17-003020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117003020/doc4.xml","form_type":"4"}},{"id":4495161,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-01-09T17:49:00.000Z","date":"2017-01-06","kind":"exercise","acquired":true,"shares":1326,"price":1.65,"value":2187.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016."}],"balance_after":106732,"source":{"system":"sec-edgar","filing":"0001209191-17-003020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117003020/doc4.xml","form_type":"4"}},{"id":4495160,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-01-09T17:49:00.000Z","date":"2017-01-06","kind":"exercise","acquired":true,"shares":5474,"price":1.265,"value":6924.61,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016."}],"balance_after":105406,"source":{"system":"sec-edgar","filing":"0001209191-17-003020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117003020/doc4.xml","form_type":"4"}},{"id":4495159,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-01-09T17:49:00.000Z","date":"2017-01-05","kind":"sale","acquired":false,"shares":2216,"price":23.0019,"value":50972.2104,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $23.00 to $23.05, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4."}],"balance_after":99932,"source":{"system":"sec-edgar","filing":"0001209191-17-003020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117003020/doc4.xml","form_type":"4"}},{"id":4495158,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-01-09T17:49:00.000Z","date":"2017-01-05","kind":"exercise","acquired":true,"shares":2216,"price":1.265,"value":2803.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 365 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 30, 2016."}],"balance_after":102148,"source":{"system":"sec-edgar","filing":"0001209191-17-003020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117003020/doc4.xml","form_type":"4"}},{"id":4577536,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2016-10-19T17:51:01.000Z","date":"2016-10-17","kind":"sale","acquired":false,"shares":2000,"price":27.5,"value":55000.0,"ownership":{"direct":false,"nature":"Held in trust for the benefit of Reporting Person's minor child"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by three irrevocable trusts administered by an independent trustee for the benefit of Reporting Person's minor children.  The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $27.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4."}],"balance_after":26000,"source":{"system":"sec-edgar","filing":"0001209191-16-146390","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116146390/doc4.xml","form_type":"4"}},{"id":4577535,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2016-10-19T17:51:01.000Z","date":"2016-10-17","kind":"sale","acquired":false,"shares":2000,"price":27.5025,"value":55005.0,"ownership":{"direct":false,"nature":"Held in trust for the benefit of Reporting Person's minor child"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by three irrevocable trusts administered by an independent trustee for the benefit of Reporting Person's minor children.  The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $27.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":26000,"source":{"system":"sec-edgar","filing":"0001209191-16-146390","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116146390/doc4.xml","form_type":"4"}},{"id":4577534,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":52683,"kind":"person","name":"Litton Mark James","position":1,"cik":"0001604834","reported_name":"Litton Mark James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2016-10-19T17:51:01.000Z","date":"2016-10-17","kind":"sale","acquired":false,"shares":2000,"price":27.4964,"value":54992.8,"ownership":{"direct":false,"nature":"Held in trust for the benefit of Reporting Person's minor child"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by three irrevocable trusts administered by an independent trustee for the benefit of Reporting Person's minor children.  The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $27.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4."}],"balance_after":26000,"source":{"system":"sec-edgar","filing":"0001209191-16-146390","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116146390/doc4.xml","form_type":"4"}}]}